Moderna’s combined Covid-19 and flu vaccine matched the efficacy of single shots in late-stage trial results published on Monday, opening the door for the mRNA vaccine maker to seek approval for its third product.
周一公布的后期试验结果显示，莫德纳(Moderna)的新冠和流感联合疫苗与单独疫苗的效力相当，这意味着这家mRNA疫苗生产商能够为其第三款产品申请许可。
您已阅读6%（289字），剩余94%（4545字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。